Director, UNC Lineberger Clinical Protocol Office

Company: UNC-Chapel Hill
Location: Chapel Hill, NC

Apply

The Director of UNC Lineberger’s Clinical Protocol Office (CPO) provides leadership and direction for the management and growth of cancer clinical trials operations. The CPO Director ensures successful execution of clinical trials operations, with responsibility and accountability for continually improving the quality and efficiency of the clinical trials office. Reporting to the CPO Medical Director, this position serves as the subject matter expert on best practices for clinical trials management and on regulations governing the conduct of clinical research. The position supervises heads of: regulatory and compliance, clinical, multi-center, protocol development and office management staff groups of the CPO, promoting cross-functional coordination. The CPO Director works collaboratively with UNC Lineberger leadership, finance and data management groups, UNC School of Medicine departments and divisions, UNC Health Care System and Cancer Network, and UNC Office of Clinical Trials to meet cancer center goals, fulfill its clinical research mission, and also contribute to clinical research best practices within the University at large.

Minimum Qualifications:

Extensive experience (seven years or more) of progressively responsible experience in clinical trials operations required. Demonstrated decision making, creative problem solving, conflict resolution, and team building skills to build, lead, manage, and mentor professional staff. Must demonstrate excellent leadership, interpersonal and communication skills, as well as the ability to collaborate effectively with internal and external stakeholders. Prior oncology clinical research supervisory/management experience in an NCI-designated cancer center or equivalent large academic institution is preferred.A master’s degree required. Clinical research management certification such as CCRP, ACRP or SOCRA is preferred.

Position Number:

NF0004015

Posting Date:

09/19/2019

Closing Date:

12/02/2019

American Recovery & Reinvestment Act Funded:

No